eli lilly was off a fraction to $80.46. merck fell also off slightly to $54.61.ore on that saga at valeant pharmaceuticals. valeant says goldman sachs sold more than 1 million valeant shares that were used as collateral for loans given to the drugmaker's chief executives. and that helped trigger yesterday's 14% drop in the stock. today shares were nearly 4% higher to $81.77. >>> well, medicare membership growth helped to increase humana's earnings. still, revenue came in below consensus, which weighed on the insurer in today session. that stock fell by 1% to $177.24. cigna also reported mixed quarterly results. revenue from premiums and fees rose. the insurer hiked the low end of its operating income forecast at the same time. shares were up 3% today to $55.87. >>> and warren buffett's berkshire hathaway saw its operating profit actually slip in the most recent quarter. that's the number the investors look at in this firm's report as it offers the best read of the conglomera conglomerate's performance. the company did see quarterly profit double following its rec

happy. >> for more informtion on the i'll be me alzheimer's fund, go to ibmaf.org. >>> on behalf of eli lilly

pfizer was trying to tie a knot and a valiant bottom that shot up and companies like biogen and eli lilly barely bruised bounced back with alacrity and because of warm weather jumped on a monster buyback dividend boost and split by nike. transports, well, they suddenly were energized by the takeover outreach by the rail company. meanwhile, the packaged goods distributor famously balked at a bid from air products five years ago got an offer from its french offer, too juicy to pass up. $143 per share, more than double, okay, the size of the earlier thwarted hostile offer from air products, and even the increased offer. even the consumer products companies with their 3% yields performed well. once we heard from the most hawkish presidents who said one hike and weight has been the mantra meaning the fed isn't going to raise interest rates on autopilot. even december seems like liftoff and, oh, fang warded higher anyway, with reports from none other than apple, two big firms pronounced in for the duration based and channel checks with suppliers and historically more wrong than right. more just

companies we look at our solid citizens, eli lilly is a good example. products they are bringing into market. cardiovascular impact, potentially on alzheimer's or breast cancer. ande are segments innovations that are solid and they certainly have not then price gougers. betty: on a final note overall in the markets, with earnings wasn'talmost over, -- it a great earnings season, but is it going to get worse? john: it's a choppy earnings season. we are not seeing a terribly strong topline growth, earnings are supported by a lot of share buybacks. but that said, we have a backdrop where we have a lot of companies and you have to be selective that you do have strong fundamentals. some are benefiting on the input side like consumer discretionary whether it's relative to fuel or other commodities on the one hand or on the other hand, their consumers are saving money at the gas pump. so they are ready to buy more of their products. there's been a bit of a hiccup and slowdown. with finer strokes, you can certainly find some opportunities. very much.k you that

. >>> on behalf of eli lilly and company, welcome to the special presentation of "glen campbell i'llor nearly 140 years, lilly has been dedicated to making life better through our medicine. and for the last quarter century, we have been working to discover treatments for alzheimer's disease. we are making progress, but a breakthrough can't come soon enough. tonight, we're proud to partner with cnn to bring you this powerful film.

getting slammed off worries about drug pricing but are there some names still worth owning besides eli lilly stick with cramer. >> don't miss a sesend of "mad money." follow@jimcramer on twitter. have a question? tweet cramer. #madtweets. send jim an e-mail to madmoney@cnbc.com. or give us a call at 1-800-743-cnbc. head to madmoney.cnbc.com. >>> later this week, we're getting one of the moswidely anticipated ipos of the year when square, the payment technology company founded by jack dorsey comes public. even for those of you who don't know square, you have almost certainly run into their products. they make lilile devices you can plug into your phone and turn itit into a credit card reader, along with the ipad stand to turn the tablet into more of a permanent point of sale terminal. you have seen them at stores. not to mention a brand new product that lets businesses accept apple pay a a other wireless payment methods. square sells you the actual device for very little. in some cases for nothing. then every time you swipe a customer's credit card they take a 2.75% cut which makes it ideal f

. >>> on behalf of eli lilly and company, welcome to the special presentation of "glen campbell i'll be me." for nearly 140 years, lilly has been dedicated to making life better through our medicine. and for the last quarter century, we have been working to discover treatments for alzheimer's disease. we are making progress, but a breakthrough can't come soon enough. tonight, we're proud to partner with cnn to bring you this powerful film. ♪ ♪ ♪ >> who is that? >> it's you, honey. >> that's me there? >> that was you. >> that is me. i don't know which one i'm holding. >> debbie, your oldest daughter. >> is that debbie? debbie. ♪ i forgot. well, who is he? >> come on, you know who that is. it's you, honey. >> oh. it's a movie about you. >> no kidding. i'll be me. ♪ >> who is that? >> that's billie. >> oh, it's my daughter. >> no, that's your second wife. >> billie. >> you were married for 16 years. you had kelly, travis and cane. >> oh, really? who is that? >> that's your third wife, sara and dylan -- and then you met me. >> she's a good looking girl. she still is. >> how many does thi

eli lilly, fine indiana company, retold you it would go higher, headquartered in indiana.hey pay taxes everywhere. not fair. not fair. in washington, what do they focus on? not this. >> yeah. >> they claim to be focused on it. >>> when we come back, the business of thanksgiving and luring the crowd that doesn't want to cook. we'll talk to the ceo of boston market gearing up for the busiest day of the year. dow trying to come off the lows here. ho, ho, hello... can you help santa with a new data plan? sure thing... uh right now you can get 15 gigs of data for the price of 10. that's five extra gigs for the same price. looks like someone just made it to the top of the nice list. in that case, i want a new bicycle, a bike helmet, a basketball, a stuffed animal that talks when you squeeze it. and... yes, yes. i got your letter. we're good. oh. okay i was just making sure. get 15 gigs for the price of 10 now at at&t. i've got a nice long life ahead. big plans. so when i found out medicare doesn't pay all my medical expenses, i looked at my options. then i got a medicare supplem

eli lilly, remember when it fell to 77. my trust said go buy. the stock at 84.ou know, nike was good. nike now is excelling. look at the chevrons, the exxons. they stopped going down despite oil touching 40. the airline stocks started to get better. cruise stocks, the biggest users of the -- the big shipping stocks, carnival. >> yeah. >> starting to come back. remarkable week for housing. the housing stocks are coming back. the rail subject to takeover bids. just a remarkable moment. it was supposed to be a bad week. >> it hasn't been. >> was what a week. >> crude hovering above that $40 level. that said, i should point out when it comes to energy and high yield, which, of course, energy is a smaller percentage of given how much value they have lost, spreads at the highs. >> the eia came out -- >> not even talking energy. just in general. >> the natural gas storage report is at an all-time high. 4 trillion cubic feet what does that mean for chesapeake? their preferreds were down more than the common stock. >> we should mention on alternative energy, sunedison, b

and merck and eli lilly say they've received an inquiry from the justice department about their drug pricing. both of them moving lower, merck is down by 1.1%. those are the headlines. let's get a big headlines from the big "b" with mr. big brian sullivan. over to you in dallas, brian. >> all right, mandy. thank you very much. we're here for a very rare and exclusive interview with kelsey warren. the ceo of energy transfer. ete, etp, fxl, and sun. doesn't do a lot of tv and we appreciate you coming on to cnbc. we had planned to come and talk to you about all these things about natural gas and oil and we will, but you and i were chatting off camera before this and you said you thought there's a chance that transcanada might actually be pleased with this decision because through all the rhetoric the pipeline may not be economic anyway. explain. >> i don't believe the pipeline has been economic for a while now. there's just not the spread. transcanada, these are bright people, very bright people. for them to go through the permitting process and all this ridiculous process they've gone

. >>> eli lilly. growth prospects through 2020 have improved meaningfully to use the language of the analyst after a number of positive pipeline developments. those include the drug for type two diabetes and a drug for psoriasis. the analyst is also optimistic about their drug for alzheimer's. the price target on the stock is 100 bucks. >> if you could get that in scramble, there's about three "x"s in that drug's name. when i saw that stock price target, i thought they have to be the high on the street. boy, was i wrong. jeffries is at $120 a share. lilly has had a great run. it's trading at 36 times trading earnings. one wonders. >>> the next stock another oil and gas name. we gave you a downgrade. here is an upgrade. anadarko petroleum. cowan and company moving them to their top pick in the space as well. they say the company was smart to drop the potential deal for apache and they add that while the stock trades in the, quote, penalty box in the near term, the sell-off in apc was overdone. the anal